/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
USANA Health Sciences, Inc. develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold throughout the world. In 2025, we generated $925 million in net sales and finished the year with approximately 387,000 active Customers in our core nutritional business.
$14.28
$0.28 (-1.92%)
Live · 07:18 PM
Operating margin is thin at 4.05%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 8.3%, steady but not accelerating. Margins contracted 3.7pp, which offsets some of the top-line progress.
Free cash flow declined 83% versus the prior year, cash generation momentum has weakened. ROIC dropped from 9.91% to 5.38%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$913M
▲ +8.3% YoY
Net Income (TTM)
-$22M
▼ -74.4% YoY
Op. Margin
-0.12%
▼ -3.7pp YoY
ROIC
-0.16%
▼ -4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$16M
▼ -83.3% YoY
Op. Cash Flow (TTM)
$28M
▼ -63.4% YoY
Net Debt
-$169M
Net Cash Position
Cash & Equiv.
$169M
5Y CAGR: -4.0%
5Y CAGR: -43.3%
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 4 Jul 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, live as of 3 Sept 2026. Fiscal year ends Jan. Sector medians are approximate S&P 500 benchmarks and update periodically.
Usana Health Sciences (USNA) trades below a two-stage DCF intrinsic value of about $24.06 per share, so at $14.28 the stock looks undervalued (68.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Usana Health Sciences scores 34/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $24.06 per share for USNA, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $18.04. At today's $14.28, that puts the stock about 68.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Usana Health Sciences scores 34 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -0.1% operating margin and a -0.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. USNA currently trades below its estimated intrinsic value and scores 34/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.